Cargando…
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial
OBJECTIVES: Primary Objective • To test the efficacy of Hydroxychloroquine (HCQ) (400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days, to complete 14 days) to prevent incident SARS-CoV-2 infection, compared to ascorbic acid among contacts of persons with SARS-CoV-2 infe...
Autores principales: | Barnabas, Ruanne V., Brown, Elizabeth, Bershteyn, Anna, Miller, R. Scott, Wener, Mark, Celum, Connie, Wald, Anna, Chu, Helen, Wesche, David, Baeten, Jared M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268961/ https://www.ncbi.nlm.nih.gov/pubmed/32493478 http://dx.doi.org/10.1186/s13063-020-04446-4 |
Ejemplares similares
-
LB-17. Efficacy of Hydroxychloroquine (HCQ) for Post-exposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Blinded, Randomized, Controlled Trial
por: Brown, Elizabeth R, et al.
Publicado: (2020) -
Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda
por: Ying, Roger, et al.
Publicado: (2015) -
Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial
por: Johnston, Christine, et al.
Publicado: (2021) -
HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery
por: Celum, Connie L, et al.
Publicado: (2019) -
Closing the gaps in the HIV care continuum
por: Barnabas, Ruanne V., et al.
Publicado: (2017)